Khan Najat 内部人交易：近期 SEC Form 4 交易
过去 18 个月，Khan Najat（CIK 2020969）在 1 家公司共报告 15 笔 SEC Form 4 内部人交易（最近一笔 2026-09-10）。
| 日期 | 公司 | 身份 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-09-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 22,408 | $78,822 |
| 2026-08-18 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 80,498 | $254,374 |
| 2026-06-05 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 23,588 | $84,445 |
| 2026-05-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 62,701 | $190,611 |
| 2026-03-11 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 28,298 | $94,798 |
| 2026-02-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 14,280 | $49,837 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 买入 | 1.7M | $0 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 买入 | 30,346 | $0 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | 卖出 | 10,364 | $41,249 |
| 2025-12-29 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 卖出 | 124,403 | $548,617 |
| 2025-11-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 卖出 | 17,584 | $72,798 |
| 2025-11-06 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 买入 | 84,925 | $0 |
| 2025-08-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 卖出 | 3,789 | $21,370 |
| 2025-08-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 卖出 | 36,599 | $202,026 |
| 2025-05-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | 卖出 | 3,796 | $16,133 |
来源：SEC Form 4 申报文件 · 截至 2026-09-10